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Infectious Disease

Antibiotic Stewardship and Overcoming Antibiotic Resistance
in Upper Respiratory Tract Infections
Katherine Elsass, Austin Hilverding, Steven Blake, Brendan Rasor, Steven N. Leonard, PharmD

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Nwnber (UAN): 0048-0000-17-002-H04-P
To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/.

Objectives
After completion of this program, the reader should be able to:
1. Describe changes outlined in the new CDC/ ACP Acute
Respiratory Tract Infection in Adults guidelines.
2. Evaluate human factors contributing to the spread of
antibiotic resistance.
3. Recognize inappropriate use of antimicrobial agents.
4. Apply IDSA recommendations for ideal antimicrobial
stewardship.
5. Describe the role of the pharmacist in antimicrobial
stewardship.

Abstract
Antibiotic resistance has rapidly become one of the most significant challenges facing modern health care. Despite widespread public education efforts by the national government
and health organizations worldwide, there remains a significant lack of public understanding of antibiotic resistance,
how to prevent it and the implications if the science and
health care communities fail to find a solution. The Centers
for Disease Control and Prevention (CDC) and the American
College of Physicians (ACP) recently published updated
guidelines for appropriate antibiotic use in upper respiratory
tract infections. These guidelines include several key recommendations for acute bronchitis, pharyngitis and acute rhinosinusitis (including the common cold). In the United
States, at least 2 million antibiotic-resistant illnesses and
23,000 deaths occur each year. These illnesses and deaths
result in a large cost to patients, payers and health care institutions. Recent research has shown that numerous human
factors, such as patient satisfaction and pressure on prescribers, have an impact on inappropriate antibiotic prescribing.
The Infectious Diseases Society of America (IDSA) has
published information on the key elements of a model antimicrobial stewardship program. Pharmacists can use this
information to help reduce inappropriate use of antibiotics
and reduce the spread of antimicrobial resistance.
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Introduction
Antibiotic resistance has rapidly become one of the most significant challenges facing modern health care. Patients and
policy makers, as well as drug manufacturers and health care
providers, all stand to be adversely impacted by resistance.
Despite widespread public education efforts by the national
government and health organizations worldwide, there remains a significant lack of public understanding of antibiotic
resistance, how to prevent it and the implications if the science and health care communities fail to find a solution. New
antibiotics are being developed at record low rates, while
inappropriate prescribing and excessive agricultural use continue to fuel the spread of drug-resistant species. As a follow
up to the Spring 2015 article on resistance, this article further explores the topic with emphasis on recent guidelines,
additional factors contributing to resistance and an expanded discussion on the pharmacist's role in minimizing the development of resistance.
Guideline Update
The Centers for Disease Control and Prevention (CDC) in
concert with the American College of Physicians (ACP) recently published guidelines for appropriate antibiotic use in
adults with acute respiratory tract infections. Inappropriate
prescribing of antibiotics leads to thousands of adverse reactions, many deaths and billions of health care dollars spent
each year.1 The publication updates guidelines from 2001
that stated, "Antibiotic treatment of adults with nonspecific
upper respiratory tract infection does not enhance illness
resolution and is not recommended."2 The updated guidelines specifically describe appropriate antibiotic use in four
acute upper respiratory tract infections.
Acute Bronchitis
The vast majority of bronchitis cases are viral in nature, and
the guidelines recommend against routine testing for
nonviral causes. 1 Treatment with antibiotics for patients
with bronchitis is generally inappropriate unless pneumonia
is suspected,1.3 Using antibiotics in patients with bronchitis is
associated with higher incidence of adverse events and insignificant treatment results compared to control data.3.4
Pharyngitis
The guidelines recommend against the use of antibiotics in
most pharyngitis cases. Pharyngitis is typically of viral origin
and self-limiting with a short presentation, so only minor
benefits are noticed with antibiotic treatment.5,6 Antibiotics
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may be useful for those patients with confirmed group A
streptococcal infection.s Confirmation of a group A streptococcal infection may be completed via traditional throat
swab on a sheep blood agar plate, but this involves a delay. 7
Commercial rapid antigen detection tests are more expensive
but allow swift identification of the microbe.7 In these patients, antibiotics may reduce duration of symptoms by up to
two days and complications such as acute rheumatic fever
may be avoided.6 Penicillin is the recommended antibiotic in
patients fitting this criteria and without allergy.1 Discretionary use of antibiotics is advised in this population.
Acute Rhinosinusitis
Viruses are normally the cause of acute rhinosinusitis, but
acute bacterial rhinosinusitis may be a secondary complication. Therefore, antibiotic treatment is recommended in
patients with persistent symptoms. This includes patients
displaying greater than 10 days of symptoms, the onset of
severe symptoms and cases of "double sickening" where patients initially improve then remit with worsening symptoms. Amoxicillin-clavulanate is the recommended treatment
for acute bacterial rhinosinusitis with doxycycline or respiratory fluoroquinolones as alternative options.1.s Other guidelines may recommend amoxicillin as the drug of choice, but
the current practice guidelines advise the need for clavulanate due to growing resistance concerns.1
Common Cold
The updated guidelines caution providers against prescribing antibiotics in cases of the common cold. Only symptomatic therapy is recommended in these patients. In addition to
inefficacy, antibiotics are associated with increased risks of
adverse drug events in patients with the common cold.1.2
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Antibiotic Resistance
The CDC defines antibiotic resistance as "the ability of mi·
crobes to resist the effects of drugs." Resistance most often
occurs due to the elimination of both harmful and beneficia.
bacteria, resulting in an optimal environment for the remain·
ing drug resistant bacteria to develop and grow.9 In the
medical community, antibiotic resistance has become an in·
creasing concern. Not only is the quality of care affected, but
the cost of sequential care escalates for the patient. In 2009,
$20 billion in health care were spent on antibiotic resistance,
with an additional $8,000 in hospital stays per patient and
$35 billion spent in societal costs from loss of productivity
due to hospitalization or death.io.11 A study conducted by
Robert et al. found that a single patient with an antibiotic
resistant infection could result in $29,069 in added costs.
However, this dollar value was based on 2008 data, meaning
there are even greater costs in present day dollar value.11
In the United States, at least 2 million antibiotic-resistant
illnesses and 23,000 deaths occur each year. Based on 2013
data from the CDC, invasive methicillin-resistant Staphylococcus aureus (MRSA) infections account for the largest
number of antibiotic resistant deaths annually, totaling
around 11,000 fatalities. Antibiotics are improperly prescribed approximately half of the time, including inappropriate duration of treatment and indication.9 A retrospective
cohort study conducted by Gill et al. evaluated 52,135 cases
of upper respiratory tract infections using electronic health
records, and found that 65 percent of patients received antibiotics. Broad-spectrum antibiotics for upper respiratory
infections were prescribed for over half of the cases, with 68
percent of broad-spectrum antibiotics being prescribed for
acute bronchitis.12 This contradicts the general guideline rec-

Table 1. Summary of CDC/ ACP Recommendations for Appropriate Antibiotic Use in Select Acute Respiratory Tract
Infections.1

Acute Respiratory
Tract Infection

Acute Bronchitis

Pharyngitis

Acute Rhinosinusitis

Common Cold

Appropriate
Antibiotic Use
Recommendation

Only if pneumonia
is suspected.

Discretionary use in
group A streptococcal
infections.

Patients with persistent
symptoms indicative of acute
bacterial rhinosinusitis.

Not recommended.
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ommendations for upper respiratory infections, which advise the year 2020.1s Although the 10 X '20 Initiative has been reagainst the use of broad-spectrum antibiotics.z
leased, along with an initiative developed by the White House
to bring new antibiotics to the market by 2020, the funding
Physicians and health care professionals often feel pressured for new antibiotic development is often not available. On Jan.
to prescribe an antibiotic for upper respiratory infections 20, 2016, more than 80 drug and medical device manufactureven when antibiotic use is not indicated. In a follow-up tele- ers requested governments along with industry leaders to
phone survey of 959 patients, conducted by Stearns et al., declare a fight against antibiotic resistance by funding the
visit satisfaction scores for treatment of upper respiratory research and development of new antibiotics. The Declaratract infections at both Veterans Administration (VA) hospital tion on Combating Antimicrobial Resistance represents a
emergency departments and non VA hospitals were studied. It monumental step in the fight against antibiotic resistance as
was found that in the non VA settings, an overall visit satisfac- commercial drug manufacturers, diagnostic developers and
tion score based on a five point Likert scale was significantly global governments unite to conserve antibiotics by focusing
increased with an antibiotic prescription, while there was no on three broad areas: redu cing the development of drug restatistical difference in scores for VA hospitals.13 Cordelia et sistance, increasing investment in research and development
al. evaluated patient satisfaction as a driving factor for health that meets global public health needs and improving access to
professionals when prescribing antibiotics for acute respira- high-quality antibiotics for alJ.16
tory tract infections. Overall, 33.7 million antibiotic prescriptions were prescribed to a population of 53.8 million patients, Antimicrobial Stewardship
with antibiotic prescriptions showing a direct correlation to ln order to meet the growing demands placed upon patient
higher doctor and practice satisfaction scores based on pa- care by antibiotic resistance and a slowdown in introduction
tient general practice surveys.14
of new antimicrobial drug classes to market, pharmacists and
other health care professionals must strive toward improved
In 2010, the IDSA announced the 10 X '20 Initiative, bringing stewardship of current antimicrobials.17 Model guidelines set
together interdisciplinary leaders to stimulate new antibacte- forth by the IDSA in 2007 detail components of an idealized
rial research and development to create 10 new antibiotics by stewardship program for implementation in various health

Table 2. Summary of 2007 IDSA Model Antimicrobial Stewardship Program. is

Guideline Measure

4

Purpose

Prospective audits with feedback

Review prescribing trends, provide one-on-one pharmacistprescriber feedback.

Formulary restriction/drug preauthorization

Curtail unnecessary antimicrobial agent prescribing, cut costs,
improve outcomes.

Provider education/guidelines

Provide awareness of current antimicrobial agent prescribing
recommendations.

Antimicrobial agent order forms

Require prescriber justification for antimicrobial agent use.

Dose-optimized therapy

Causative organism-specific therapy to curtail antimicrobial
resistance development.

Parenteral to oral conversion

Decrease hospital stay length, decrease overall cost.

Computer-based clinical decision support

Provide real-time therapy recommendations to improve adherence to antimicrobial prescribing guidelines.
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care settings.rn Components include utilization of prospective, ongoing audits with provider intervention and feedback;
formulary restrictions and/or antimicrobial agent preauthorization; provider education and guidelines; use of antimicrobial agent order forms; streamlined, dose-optimized therapy;
parenteral to oral conversion as appropriate; and computerbased clinical decision support, surveillance and feedback.
In the IDSA model, prospective audits with intervention and
feedback involve direct interaction between an infectiousdiseases trained physician or pharmacist and the prescriber.18 In addition to this consult, the use of clinical guidelines
and other modes of health care professional education have
been met with mixed results.1 9 Potential provider education
measures include educational pamphlets, outreach events
and one-on-one consultations with prescribers. However,
education must be coupled with active intervention or the
educational interventions will have only a marginal impact
on prescribing practices.1a Formulary restrictions and/or
antimicrobial agent preauthorization can involve obtaining
special approval from an advisory board before initiation of a
restricted antimicrobial. Via such methods, the use of otherwise potentially unnecessary or redundant antimicrobials
can be curtailed leading to significant cost reductions and
improvements in overall patient health. Additionally, an appeals process and constant monitoring must be available to
ensure judicious execution of a preauthorization program.
Other components of a model stewardship program include
the use of antimicrobial ordering forms to improve patient
outcomes and decrease antimicrobial usage. 18 Such forms
require prescribers to justify drug choice when initiating
or continuing therapy. Antimicrobial ordering forms must be
coordinated with appropriate, streamlined antimicrobial use.
Therapy must be specific to the causative organism, as unnecessary use of broad-spectrum or combination therapy can
contribute to the development of antimicrobial-resistant
pathogens.20 Additionally, antimicrobials must be dosed appropriately to ensure adequate antimicrobial action without
facilitating the development of resistance.10 In addition to
appropriate drug selection and dosage, the route of administration also plays an important role in infection treatment,
as converting antimicrobials from parenteral to oral administration when clinically appropriate can decrease hospital
stay length and overall costs.
A final component of a model stewardship program includes
the use of computerized monitoring and clinical decision
support.18 In this model, real-time recommendations are displayed in the electronic medical records system when a prescriber inputs an order. These recommendations can require
immediate prescriber attention before allowing completion
of the order or may appear as optional advice. Such programs have demonstrated improved adherence to and physician acceptance of antimicrobial prescribing guidelines.21.22
Overall, the use of model stewardship guidelines decreases
overall antimicrobial usage, health care cost, and hospital
stay length and improves patient outcomes.

Update on New IDSA Guidelines
The IDSA published updated stewardship guidelines in April
2016.23 This update provides further guidance on how to
implement a stewardship program while stressing the
importance of individualizing programs according to each
clinical site's characteristics, resources and needs. Table 3
provides a review of the new recommendations found in the
updated guidelines.

Role of the Pharmacist
Pharmacists play a key role in the promotion of antimicrobial
stewardship. In the institutional setting, pharmacists often
work closely with hospital staff to monitor patient therapy
and ensure the correct drug selection, dosage and route of
administration. More significantly, pharmacists are frequently responsible for the daily implementation of stewardship
programs in clinical settings, including management and policy development. In the community setting, pharmacists can
counsel patients, educating them on the importance of antimicrobial medication adherence.24 Additionally, they can
immunize patients and lead other public health initiatives.
However, where pharmacists currently have the greatest
potential to impact antimicrobial resistance is through collaborative practice with other health care professionals.
An important role for pharmacists in collaborative practice
includes triage, where pharmacists assess the severity of a
patient's symptoms including the appropriateness of
self-treatment with over-the-counter medications or if the
condition requires a physician's visit.24 Other collaborative
practice examples include community pharmacists outside
the United States (such as in Canada, the United Kingdom
and New Zealand) who have entered into practice agreements with physicians where they can directly monitor and
prescribe limited antimicrobials. Generally, these programs
have been met with success and exemplify the potential of
such agreements in the United States. In the hospital setting,
pharmacists can lead antimicrobial stewardship teams, heading the fight against growing antimicrobial resistance by
implementing model stewardship programs. Significantly,
recent initiatives from the President's Council of Advisors on
Science and Technology and the Centers for Medicare and
Medicaid Services indicate a regulatory requirement for Antimicrobial Stewardship Programs (ASPs) in clinical settings,
with projected implementation by 2017, and represent a potential role for pharmacists.zs Overall, pharmacists play
an instrumental role in leading and working with other
health care professionals in the fight against antimicrobial
resistance.
Conclusion
While antimicrobial resistance remains an urgent challenge
to modern health care, significant steps have been taken in
an effort to curtail the spread of resistant organisms. New
treatment guidelines help prescribers to better utilize current antimicrobials and to keep up with a rapidly changing
field. The pharmaceutical industry has united to help provide
new antibiotics and find new ways of treating infections.
Governments and health organizations continue to educate
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Table 3. Summary of the 28 Specific Recommendations from the 2016 IDSA Updates to Model Antimicrobial
Stewardship Program (ASP).23

Guideline
Measure

Recommend

Evidence
Strength

Low

Aminoglycoside
pharmacokinetic
monitoring/
adjustment

Yes

Moderate

Low

Vancomycin
pharmacokinetic
monitoring/
adjustment

Yes

Low

Low

Rapid viral testing use
to reduce inappropri- Yes
ate antimicrobial use

Low

Alternative dosing
strategies to avoid
broad-spectrum Yes
~-lactam dosing
for cost concerns

Low

Low

Rapid diagnostic
testing with routine
testing

Moderate

Appropriate IV to
oral antimicrobial Yes
conversion*

Moderate

Moderate

Serial Procalcitonin
Testing in Intensive
Care Unit patients to Yes
decrease antimicrobial use

Moderate

Allergy assessment and penicilYes
!in skin testing for
~-lactam allergy

Low

Low

Use nonculture-based
fungal markers in
hematologic maligYes
nancy to optimize
antifungal use

Low

Use shortest effective duration of
Yes
treatment*

Moderate

Moderate

Monitor antimicrobial
use via Days ofTheraYes
PY instead of Defined
Daily Dose

Low

Consider goals
and size for
Yes
syndrome-specific
intervention

Good
practice
recommendation

Low

Antimicrobial cost
measured by
prescription/
Yes
administration history
instead of purchasing
data

Develop facilityspecific guidelines
for fever and
Good practice
neutropenia
Yes
recommendation
management in
hematologyoncology patients

Low

Low

ASP implementation
in nursing/skilled
nursing homes

ASP implementaGood practice
tion in Neonatal
recommendation Intensive Care
Units

Yes

Good
practice
recommendation

ASP implementation in terminally Yes
ill patients

Good
practice
recommendation

Guideline
Measure

Moderate

Develop stratified
antibiograms for
empiric therapy
guideline
development

Low

Selective reporting
of antimicrobial
susceptibility test
results

Yes

Specific
infectious disease
Yes
syndrome-targeted
interventions

?reauthorization/
Prospective
Audit/Feedback
Intervention*

Recommend

Evidence
Strength

Evidence
Strength

Guideline
Measure

Yes

Do not
Didactic education*
use alone

Facility-specific
practice guidelines

Reduce use of high
risk Clostridium
difficile infectionassociated
antimicrobials
Prescriber-led
routine review of
antibiotic usage•

Computerized
clinical decision
support*

Antibiotic cycling

Yes

Yes

Yes

No

ASP implementation in immunocompromised patients Yes
to improve antifungal treatment

Recommend

Yes

Yes

Yes

Yes

*Recommendation previously found in 2007 guidelines
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the public on how to do their part. Within health care
practice, antimicrobial stewardship programs have become
widespread and standardized. Through all of these changes,
pharmacists remain at the forefront in each effort. Pharmacists are among the best prepared health care providers
fighting to end the threat of widespread antimicrobial
resistance.
References
1.
Harris AM, Hicks LA, Qaseem A. Appropriate antibiotic use for acute
respiratory tract infection in adults: advice for high-value care from the
American College of Physicians and the Centers for Disease Control and
Prevention. Ann Intern Med. 2016;164(6):425-34.
2. Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR,
Sande MA. Principles of appropriate antibiotic use for treatment of
acute respiratory tract infections in adults: background, specific aims,
and methods. Ann Intern Med. 2001Mar20;134(6):479-86.
3. Smith SM, Fahey T, Smucny), Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. Mar 2014;(3). Available from:onlineli
brary.wiley.com/doi/10.1002/14651858.CD000245.puh3/full.
4.
Llor C, Moragas A, Bayona C, Morros R, Pera H, Plana-Ripoll 0, et al.
Efficacy of anti-inflammatory or antibiotic treatment In patients with
non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial. BM). 2013;347:f5762. Available from :
www.bmj.com/content/347 /bmj.15762.
S. Shulman ST, Blsno AL, Clegg HW, Gerber MA, Kaplan EL, Lee G, et al.
Clinical practice guideline for the diagnosis and management of group
A streptococcal pharyngitis: 2012 update by the Infectious Diseases
Society of America. Clin Infect Dis. 2012;55(10):e86-e102. Available
from:/ /cid.oxfordjournals.org/ content/SS /10 I e86.full.
6.
Spinks A, Glasziou PP, Del Mar CB. Antibiotics for sore throat. Cochrane
Database Syst Rev. 2013;(11). Available from:onlinelibrary.wiley.com/
doi/10.1002/14651858.CD000023.pub4/full.
7.
Gerber MA, Shulman ST. Rapid Diagnosis of Pharyngitis Caused by
Group A Streptococci. Clin Microb_iol Rev. 2004;17(3):571-80.
8. Chow AW, Benninger MS, Brook I, Brozek)L, Goldstein EJC, Hicks LA, et
al. Executive summary: IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54
(8):1041-5. Available from:cid.oxfordjournals.org/content/54/8/1041.
long.
9.
Centers for Disease Control and Prevention. [Internet]. Atlanta (GA):
Centers for Disease Control and Prevention. About Antimicrobial Resistance; (Updated 2015 Sep 8; cited 2016 April 1]; [about 8 screens] .
Available from:www.cdc.gov/drugresistance/about.html.
10. Bush K. Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, et al.
Tackling antibiotic resistance. Nat Rev Microbial. 2011 Nov 2;9
(12):894-6.
11. Roberts RR, Hota B, Ahmad I, Scott D, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago
teaching hospital: implications for antibiotic stewardship. Clin Infect
Dis. 2009Oct15;49(8):1175-84.
12. Gill JM, Flelschut P, Haas S, Pellini B, Crawford A, Nash DB. Use of antibiotics for adult upper respiratory infections in outpatient settings: a
national ambulatory network study. Fam Med. 2006 May;38(5):349-54.
13. Stearns CR, Gonzales R, Camargo CA Jr, Maelli J, Metlay JP. Antibiotic
prescriptions are associated with increased patient satisfaction with
emergency department visits for acute respiratory tract infections.
Acad Emerg Med. 2009 Oct;16(10):934-41.
14. Ashworth M, White P, Jongsma H, Schofield P, Armstrong D. Antibiotic
prescribing and patient satisfaction in primary care in England: crosssectional analysis of national patient survey data and prescribing data.
British Journal of Gen Practice. 2016 Jan; 66(642): 40-6.
15. Infectious Diseases Society of America. The 10 x '20 initiative: pursuing
a global commitment to develop 10 new antibacterial drugs by 2020.

Infectious Diseases

Clin Infect Dis. 2010 April 15; 50(8):1081-3.
16. Global pharmaceutical industry calls on governments to work with
them to beat the rising threat of drug resistance [Internet]. London,
England: HM Government; 2016 Jan 21 [cited 2016 April 1]. Available
from:amr-review.org/sites/default/files/Press%20notice%20Jan%20
21%202016.pdf.
17. Bond CM. Antibiotic stewardship: an important pharmacy role? Can J
Hosp Pharm. 2015 Nov-Dec;68(6):441-2.
18. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP,
et al. Infectious Diseases Society of America and the Society for Health
care Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007
Jan 15;44:159-77.
19. Arnold AR, Strauss SE. Interventions to improve antibiotic prescribing
practices in ambulatory care (review). Cochrane Database Syst Rev.
2005 July 31;4:1-78.
20. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill
patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis.
2003Apr15;36:1006-12.
21. Nachtigall I, Tafelski S, Deja M, Halle E, Grebe MC, Tamarkin A, et al.
Long-term effect of computer-assisted decision support for antibiotic
treatment in critically ill patients: a prospective 'before/after' cohort
study. BMJ Open. 2014 Dec 22;4(12):e005370.
22. Chow AL, Ang A, Chow CZ, Ng TM, Teng C, Ling LM, et al. Implementation hurdles of an interactive, integrated, point-of-care computerised
decision support system for hospital antibiotic prescription. Int J Antimicrob Agents. 2016 Feb;4 7(2):132-9.
23. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus
EJ, et al. Implementing an antibiotic stewardship program: guidelines
by the Infectious Diseases Society of America and the Society for Health
care Epidemiology of America. Clin Infect Dis. 2016 April 15;62:1-27.
24. International Pharmaceutical Federation. Fighting antimicrobial resistance: the contribution of pharmacists. The Hague: International
Pharmaceutical Federation; 2015.
25. Goff D. NFID News [blog on the Internet]. Bethesda (MD): National
Foundation for Infectious Diseases. Presidential order pushes mandatory antimicrobial stewardship: is your hospital prepared?; 2015 Apr
16 [2016 Apr 22]; [about 2 screens]. Available from:nfid.wordpress.
com/2015/04/16/presidential-order-pushes-mandatory-antimicrobi
al-stewardship-is-your-hospital-prepared/.
The authors have no conflict of interest or funding support to disclose.

Summer 2016 Volume 7, Issue 3 THE PHARMACY AND WELLNESS REVIEW

7

Antibiotic Stewardship and Overcoming Antibiotic Resistance in Upper Respiratory Tract Infections

Infectious Diseases

-----------------------------------------------------------

Assessment Questions
1.

Antibiotics are never appropriate in patients with acute
respiratory tract infections.
A. True
B. False

2.

Which of the following statements about appropriate
antibiotic use is correct?
A. Recent advances show minor usefulness of antibiotic treatment of patients with a common cold.
B. Inappropriate antibiotic use is not a concern in
well-developed hospitals across the United
States.
C. Inappropriate antibiotic use is often associated
with insignificant treatment outcomes as well as
higher rates of adverse reactions.
D. Inappropriate antibiotic use is not associated
with antibiotic resistance although the two topics are often discussed in tandem.

3.

According to recent data, how much money is spent on
antibiotic resistance annually?
A. $1 billion
B. $2 billion
C. $10 billion
D. $20 billion

4.

Antibiotic prescribing is not relevant to a health care
provider's overall patient satisfaction scores.
A. True
B. False

5.

According to the CDC, antibiotics are incorrectly prescribed what percent of the time?
A. 30%
B. 20%
c. 50%
D. 60%

6.

Which of the following is NOT a part of a model stewardship program?
A. Computer-based decision support
B. Prospective, ongoing audits with HCP intervention and feedback
C. Formulary restrictions
D. Antimicrobial agent postauthorizations
E. Use of antimicrobial agent order forms

8

7.

Streamlined antimicrobial therapy should:
A. Be targeted to the organism when such information is known.
B. Be wide-spectrum when the target organism is
known.
C. Utilize the optimal dose for maximal antimicrobial action while minimizing chance of antibiotic
resistance development.
D. Both A and B.
E. Both A and C.

8.

Which of the following MOST ACCURATELY describes
the role of the pharmacist in antibiotic stewardship?
A. The pharmacist plays a role in prescribing the
appropriate antibiotic at the optimal dose.
B. The pharmacist plays a role in administering the
antibiotic directly to the patient.
C. The pharmacist plays a role in overseeing all
personnel in the hospital and ensuring their
compliance with institutional stewardship
guidelines.
D. The pharmacist plays a role in ensuring appropriate antibiotics are prescribed, including consulting with prescribers and patients to ensure
best practices.
E. The pharmacist does not play any significant
role in antibiotic stewardship.

9.

The IDSA recommends what action in order to maximize
the impact of provider education regarding appropriate
use of antimicrobials?
A. Active intervention
B. Presentations and posters
C. Informational pamphlets
D. Use of the most recent prescribing guidelines
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